Facts & Figures

From its roots in Mainz, Germany, BioNTech is driven to become the leading global biotechnology company for individualized cancer medicine. Since its inception, the company has raised over 1 billion in Seed and Series A financing as well as partnership investments and has become the largest privately held biotechnology company with over 1000 employees.

Management

Prof. Ugur Sahin, M.D.
Sean Marett
Sierk Poetting, Ph.D.
PD Dr. Özlem Türeci, M.D.

Employees

>1000 (March 2019)

Headquarters

Mainz, Germany

Founding Year

2008

Founded By

Prof. Ugur Sahin, M.D.
Prof. Christoph Huber, M.D.
as Spin-off of
Johannes Gutenberg University
Mainz

Locations

Mainz, Germany
Berlin, Germany
Idar-Oberstein, Germany
Neuried, Germany

Space

111944.67 square feet including
Research and Development, labs,
offices and GMP facilities

Investors

Strüngmann Family Office
MIG Fonds
Salvia GmbH
Redmile Group
Janus Henderson Investors
Invus
Fidelity Management & Research Company
Different European family offices

Affiliates

BioNTech RNA Pharmaceuticals GmbH
BioNTech Diagnostics GmbH
BioNTech Protein Therapeutics GmbH
BioNTech Cell & Gene Therapies GmbH
BioNTech Small Molecules GmbH
JPT Peptide Technologies GmbH
BioNTech Innovative Manufacturing Services GmbH

Core Technologies

mRNA : RNA-based Immunotherapies
Cell & Gene: T Cell Receptor (TCR) /Chimeric Antigen Receptor (CAR)-T Cell Therapies
Protein Therapeutics : Bispecific antibodies;
Microbodies; Virus Like Particles (VLP)

Clinical Programs

6 clinical trials on-going

Partners